Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

31 Dec 2010

Abstract excerpt

INTRODUCTION: the results of conventional treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) remain poor and innovative strategies are warranted. With this aim, epigenetic modulation became a promising approach over the last years. Vorinostat is an epigenetic targeted drug belonging to the histone deacetylase (HDAC) inhibitors family. It is the second-generation HDAC inhibitor that has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21192773
DOI: 10.1517/13543784.2011.542750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vorinostat in acute myeloid leukemia and myelodysplastic syndromesPMID 21192773Read ↗

HDAC Inhibitors in Acute Myeloid LeukemiaSemantic proximity Read ↗

Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular MechanismsSemantic proximity Read ↗

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemiaSemantic proximity Read ↗

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Semantic proximity Read ↗

The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformationsSemantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences.Semantic proximity Read ↗

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.Semantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.